# A Long-term Study of AK102 in Patients With Hypercholesterolemia

Study · id `cardio:ct-nct04173403` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04173403](<https://clinicaltrials.gov/study/NCT04173403>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04173403

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 796 participants.

## Technical summary

Registry record NCT04173403. Allocation not applicable; no masking; primary purpose treatment. Start 2019-11-04 (actual); primary completion 2023-02-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 796 participants (enrolled count; ClinicalTrials.gov record NCT04173403, source copy `cardio:ctgov-nct04173403-2023-03-02`, retrieved 2026-10-31)
- Started: 2019-11-04 (actual) (ClinicalTrials.gov record NCT04173403, source copy `cardio:ctgov-nct04173403-2023-03-02`, retrieved 2026-10-31)
- Primary completion: 2023-02-17 (actual) (ClinicalTrials.gov record NCT04173403, source copy `cardio:ctgov-nct04173403-2023-03-02`, retrieved 2026-10-31)
- Completion: 2023-02-17 (actual) (ClinicalTrials.gov record NCT04173403, source copy `cardio:ctgov-nct04173403-2023-03-02`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04173403, source copy `cardio:ctgov-nct04173403-2023-03-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04173403-2023-03-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Long-term Study of AK102 in Patients With Hypercholesterolemia
- Condition: Hypercholesterolemia
- Intervention (Drug): 450mg AK102
- Intervention (Drug): 300mg AK102
- Intervention (Drug): 150mg AK102
- Intervention (Drug): Statins and/or Ezetimibe
- Lead sponsor: Akeso
- Lead sponsor class: INDUSTRY
- Collaborator: AD Pharma (Guangdong)
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Akeso (`cardio:org-akeso`)

## Provenance

Content hash: d129ee7ebb3301cc479703760913f9a858824e7897e39c2ef9e0c2a1c982da16
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
